Long-term CD4+ lymphocyte response following HAART initiation in a U.S. Military prospective cohort

AIDS Research and Therapy

Volumn 8, Issue , 2011, Pages

  Lifson, Alan R ^a,f   Krantz, Elizabeth M ^a,f   Eberly, Lynn E ^a,f   Dolan, Matthew J ^b   Marconi, Vincent C ^c   Weintrob, Amy C ^d,f   Crum Cianflone, Nancy F ^e,f   Ganesan, Anuradha ^d,f   Grambsch, Patricia L ^a,f   Agan, Brian K ^f  

^a UNIVERSITY OF MINNESOTA   (United States)

^b WILFORD HALL MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^f UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARMY; ARTICLE; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; DISEASE COURSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROCONVERSION; VIRUS LOAD;

EID: 78651443087     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/1742-6405-8-2     Document Type: Article

References (37)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2009, 1-161. Dept. Health and Human Services, Panel on Antiretroviral Guidelines for Adults and Adolescents., http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
2. Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, Gatell JM, Günthard HF, Hammer SM, Hirsch MS, Jacobsen DM, Reiss P, Richman DD, Volberding PA, Yeni P, Schooley RT. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA Panel. JAMA 2010, 304:321-33. 10.1001/jama.2010.1004, 20639566.
3. Baker JV, Peng G, Rapkin J, Krason D, Reilly C, Cavert WP, Abrams DI, MacArthur RD, Henry K, Neaton JD, . Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk for AIDS and non-AIDS diseases. J Acquir Immune Defic Syndr 2008, 48:541-6. 10.1097/QAI.0b013e31817bebb3, 18645520, Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA).
4. Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per μL in Europe and North America: a pooled cohort observational study. Lancet 2010, 376:340-5. 10.1016/S0140-6736(10)60932-4, 20638118, Study Group on Death Rates at High CD4 Count in Antiretroviral Naive Patients.
5. Lawn SD, Little F, Bekker LG, Kaplan R, Campbel E, Orrell C, Wood R. Changing mortality risk associated with CD4 cell response to antiretroviral therapy in South Africa. AIDS 2009, 23:335-42. 10.1097/QAD.0b013e328321823f, 19114870.
6. Pakker NG, Notermans DW, de Boer RJ, Roos MT, de Wolf F, Hill A, Leonard JM, Danner SA, Miedema F, Schellekens PT. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med 1998, 4:208-14. 10.1038/nm0298-208, 9461195.
7. Battegay M, Nüesch R, Hirschel B, Kaufmann GR. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis 2006, 6:280-7. 10.1016/S1473-3099(06)70463-7, 16631548.
8. Bucy RP, Hockett RD, Derdeyn CA, Saag MS, Squires K, Sillers M, Mitsuyasu RT, Kilby JM. Initial increase in blood CD4+ lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 1999, 103:1391-8. 10.1172/JCI5863, 408455, 10330421.
9. Hunt PW, Deeks SG, Rodriguez B, Valdez H, Shade SB, Abrams DI, Kitahata MM, Krone M, Neilands TB, Brand RJ, Lederman MM, Martin JN. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS 2003, 17:1907-1915. 10.1097/00002030-200309050-00009, 12960823.
10. Smith K, Aga E, Bosch RJ, Valdez H, Connick E, Landay A, Kuritzkes D, Gross BH, Francis IR, McCune JM, Kessler H, Lederman M. Long-term changes in circulating CD4 T lymphocytes in virologically suppressed patients after 6 years of highly active antiretroviral therapy. AIDS 2004, 18:1953-6. 10.1097/00002030-200409240-00012, 15353982.
11. Landay A, da Silva BA, King MS, Albrecht M, Benson C, Eron J, Glesby M, Gulick R, Hicks C, Kessler H, Murphy R, Thompson M, White AC, Wolfe P, McMillan FI, Hanna GJ. Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment. Clin Infect Dis 2007, 44:749-54. 10.1086/511681, 17278071.
12. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007, 44:441-6. 10.1086/510746, 17205456.
13. Gras L, Kesselring AM, Griffin JT, van Sighem AI, Fraser C, Ghani AC, Miedema F, Reiss P, Lange JM, de Wolf F, . ATHENA, Netherlands National Observational Cohort Study CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr 2007, 45:183-92. 10.1097/QAI.0b013e31804d685b, 17414934, ATHENA, Netherlands National Observational Cohort Study.
14. Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M, . Swiss HIV Cohort Study Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/μL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005, 41:361-72. 10.1086/431484, 16007534, Swiss HIV Cohort Study.
15. Khanna N, Opravil M, Furrer H, Cavassini M, Vernazza P, Bernasconi E, Weber R, Hirschel B, Battegay M, Kaufmann GR, . Swiss HIV Cohort Study CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. Clin Infect Dis 2008, 47:1093-101. 10.1086/592113, 18783328, Swiss HIV Cohort Study.
16. Nash D, Katyal M, Brinkhof MW, Keiser O, May M, Hughes R, Dabis F, Wood R, Sprinz E, Schechter M, Egger M, . ART-LINC Collaboration of IeDEA Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS 2008, 22:2291-302. 10.1097/QAD.0b013e3283121ca9, 2794130, 18981768, ART-LINC Collaboration of IeDEA.
17. García F, de Lazzari E, Plana M, Castro P, Mestre G, Nomdedeu M, Fumero E, Martínez E, Mallolas J, Blanco JL, Miró JM, Pumarola T, Gallart T, Gatell JM. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr 2004, 36:702-13.
18. Kelley CF, Kitchen CM, Hunt PW, Rodriguez B, Hecht FM, Kitahata M, Crane HM, Willig J, Mugavero M, Saag M, Martin JN, Deeks SG. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis 2009, 48:787-94. 10.1086/597093, 2720023, 19193107.
19. Mocroft A, Phillips AN, Gatell J, Ledergerber B, Fisher M, Clumeck N, Losso M, Lazzarin A, Fatkenheuer G, Lundgren JD, . EuroSIDA study group Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 2007, 370:407-13. 10.1016/S0140-6736(07)60948-9, 17659333, EuroSIDA study group.
20. Lok JJ, Bosch RJ, Benson CA, Collier AC, Robbins GK, Shafer RW, Hughes MD, . ALLRT team Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection. AIDS 2010, 24:1867-76. 10.1097/QAD.0b013e32833adbcf, 20467286, ALLRT team.
21. Guihot A, Tubiana R, Breton G, Marcelin AG, Samri A, Assoumou L, Goncalves E, Bricaire F, Costagliola D, Calvez V, Rouzioux C, Autran B, Katlama C, Carcelain G, , . ALT-ANRS CO-15 study group, DECAMUNE study group Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy. AIDS 2010, 24:614-17. 10.1097/QAD.0b013e32833556f3, 19952710, ALT-ANRS CO-15 study group, DECAMUNE study group.
22. Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, Horberg MA, Saag MS, Kitahata MM, Justice AC, Gebo KA, Eron JJ, Rourke SB, Gill MJ, Rodriguez B, Sterling TR, Calzavara LM, Deeks SG, Martin JN, Rachlis AR, Napravnik S, Jacobson LP, Kirk GD, Collier AC, Benson CA, Silverberg MJ, Kushel M, Goedert JJ, McKaig RG, Van Rompaey SE, Zhang J, Moore RD, . North American AIDS Cohort Collaboration on Research and Design Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis 2010, 50:1512-20. 10.1086/652650, 20415573, North American AIDS Cohort Collaboration on Research and Design.
23. Keruly JC, Moore RD. Immune status at presentation to care did not improve among antiretroviral-naive persons from 1990 to 2006. Clin Infect Dis 2007, 45:1369-74. 10.1086/522759, 17968837.
24. Cole SR, Li R, Anastos K, Detels R, Young M, Chmiel JS, Muñoz A. Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies. Stat Med 2004, 23:3351-63. 10.1002/sim.1579, 15493031.
25. Marconi VC, Grandits GA, Weintrob AC, Chun H, Landrum ML, Ganesan A, Okulicz JF, Crum-Cianflone N, O'Connell RJ, Lifson A, Wortmann GW, Agan BK, . the Infectious Disease Clinical Research Program HIV Working Group (IDCRP) Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study. AIDS Res Ther 2010, 7:14. 2894737, 20507622, the Infectious Disease Clinical Research Program HIV Working Group (IDCRP).
26. Brodine SK, Shaffer RA, Starkey MJ, Tasker SA, Gilcrest JL, Louder MK, Barile A, VanCott TC, Vahey MT, McCutchan FE, Birx DL, Richman DD, Mascola JR. Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Ann Intern Med 1999, 131:502-6.
27. Chun HM, Fieberg AM, Huppler Hullsiek K, Lifson AR, Crum-Cianflone NF, Weintrob AC, Ganesan A, Barthel RV, Bradley WP, Agan BK, Landrum ML, . Infectious Disease Clinical Research Program HIV Working Group Epidemiology of Hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years. Clin Infect Dis 2010, 50:426-36. 10.1086/649885, 20047484, Infectious Disease Clinical Research Program HIV Working Group.
28. Centers for Disease Control 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41(RR-17):1-19. Centers for Disease Control.
29. Weintrob AC, Grandits GA, Agan BK, Ganesan A, Landrum ML, Crum-Cianflone NF, Johnson EN, Ordóñez CE, Wortmann GW, Marconi VC, . IDCRP HIV Working Group Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care. J Acquir Immune Defic Syndr 2009, 52:574-580. 10.1097/QAI.0b013e3181b98537, 19755913, IDCRP HIV Working Group.
30. World Health Organization Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents, November 2009. 2009, 1-24. Geneva: WHO, World Health Organization., http://www.who.int/hiv/pub/arv/rapid_advice_art.pdf
31. McKinnon LR, Kimani M, Wachihi C, Nagelkerke NJ, Muriuki FK, Kariri A, Lester RT, Gelmon L, Ball TB, Plummer FA, Kaul R, Kimani J. Effect of baseline HIV disease parameters on CD4+ T cell recovery after antiretroviral therapy initiation in Kenyan women. PLoS One 2010, 5:e11434. 10.1371/journal.pone.0011434, 2896395, 20625393.
32. Negredo E, Massanella M, Puig J, Pérez-Alvarez N, Gallego-Escuredo JM, Villarroya J, Villarroya F, Moltó J, Santos JR, Clotet B, Blanco J. Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications. Clin Infect Dis 2010, 50:1300-8. 10.1086/651689, 20367229.
33. Gazzola L, Tincati C, Bellistrì GM, Monforte A, Marchetti G. The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis 2009, 48:328-37. 10.1086/595851, 19123868.
34. Lange CG, Lederman MM, Medvik K, Asaad R, Wild M, Kalayjian R, Valdez H. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS 2003, 17:2015-23. 10.1097/00002030-200309260-00002, 14502004.
35. Valdez H, Connick E, Smith KY, Lederman MM, Bosch RJ, Kim RS, St Clair M, Kuritzkes DR, Kessler H, Fox L, Blanchard-Vargas M, Landay A, . AIDS Clinical Trials Group Protocol 375 Team Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002, 16:1859-66. 10.1097/00002030-200209270-00002, 12351945, AIDS Clinical Trials Group Protocol 375 Team.
36. Pitrak DL, Bolaños J, Hershow R, Novak RM. Discordant CD4 T lymphocyte responses to antiretroviral therapy for HIV infection are associated with ex-vivo rates of apoptosis. AIDS 2001, 15:1317-9. 10.1097/00002030-200107060-00018, 11426081.
37. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, Deeks SG. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003, 187:1534-43. 10.1086/374786, 12721933.